Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.58 |
| ▸ | NOS2 | P35228 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.42 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.42 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719658 | 0.81 | ALDH1A1 (0.59) | NOS1NOS2POLBTDP1ALDH1A1 | |
| SCHEMBL3656023 | 0.76 | ALDH1A1 (0.48) | NOS1NOS2POLBTDP1ALDH1A1 | |
| SCHEMBL579924 | 0.73 | NOS1 (1.00) | NOS1NOS2TDP1ALDH1A1TXNRD1 | |
| SCHEMBL11540231 | 0.73 | ALDH1A1 (0.44) | POLBTDP1ALDH1A1FGFR1MEN1 | |
| SCHEMBL27228472 | 0.73 | POLB (0.43) | NOS1NOS2POLBTDP1ALDH1A1 | |
| SCHEMBL7536750 | 0.72 | NOS1 (0.56) | NOS1NOS2TDP1ALDH1A1MAPT | |
| SCHEMBL31169320 | 0.71 | ADORA2A (0.44) | POLBTDP1ALDH1A1FGFR1MAPT | |
| SCHEMBL14909620 | 0.71 | ALDH1A1 (0.43) | NOS1NOS2POLBTDP1ALDH1A1 | |
| SCHEMBL5861345 | 0.71 | ALDH1A1 (0.49) | NOS1NOS2POLBTDP1ALDH1A1 | |
| SCHEMBL11010679 | 0.70 | MEN1 (0.46) | POLBTDP1ALDH1A1GPR35MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005417-A1 | Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| CN-101133034-A | Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments | ESTEVE LABOR DR (ES) | 2008-02-27 | — | — | CN | disclosed |
| EP-1869002-A1 | SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006069809-A1 | SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676841-A1 | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments | Esteve Laboratorios Dr. Esteve S.A. (ES) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005417-A1 | Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments | HTR6, TPH2, HTR5A | NOS1 1524/4885NOS2 434/4885POLB 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.